488 related articles for article (PubMed ID: 7604807)
61. Flow cytometric assessment of effects of fluvastatin on low-density lipoprotein receptor activity in stimulated T-lymphocytes from patients with heterozygous familial hypercholesterolemia.
Raungaard B; Brorholt-Petersen JU; Jensen HK; Faergeman O
J Clin Pharmacol; 2000 Apr; 40(4):421-9. PubMed ID: 10761170
[TBL] [Abstract][Full Text] [Related]
62. Genetic determinants of responsiveness to the HMG-CoA reductase inhibitor fluvastatin in patients with molecularly defined heterozygous familial hypercholesterolemia.
Leitersdorf E; Eisenberg S; Eliav O; Friedlander Y; Berkman N; Dann EJ; Landsberger D; Sehayek E; Meiner V; Wurm M
Circulation; 1993 Apr; 87(4 Suppl):III35-44. PubMed ID: 8462179
[TBL] [Abstract][Full Text] [Related]
63. The Lipoprotein and Coronary Atherosclerosis Study (LCAS): design, methods, and baseline data of a trial of fluvastatin in patients without severe hypercholesterolemia.
West MS; Herd JA; Ballantyne CM; Pownall HJ; Simpson S; Gould L; Gotto AM
Control Clin Trials; 1996 Dec; 17(6):550-83. PubMed ID: 8974213
[TBL] [Abstract][Full Text] [Related]
64. Effect of fluvastatin on lipoprotein profiles in treating renal transplant recipients with dyslipoproteinemia.
Li PK; Mak TW; Chan TH; Wang A; Lam CW; Lai KN
Transplantation; 1995 Oct; 60(7):652-6. PubMed ID: 7570971
[TBL] [Abstract][Full Text] [Related]
65. Effects of fluvastatin, a new inhibitor of HMG-CoA reductase, and niceritrol on serum lipids, lipoproteins and cholesterol ester transfer activity in primary hypercholesterolemic patients.
Sasaki J; Yamamoto K; Kobori S; Setoguchi Y; Sato Y; Matsunaga A; Shichiri M; Sakai T; Kono S; Arakawa K
Int J Clin Pharmacol Ther; 1995 Jul; 33(7):420-6. PubMed ID: 7582401
[TBL] [Abstract][Full Text] [Related]
66. Efficacy and safety of fluvastatin, a new HMG CoA reductase inhibitor, in elderly hypercholesterolaemic women.
Baggio G; De Candia O; Forte PL; Mello F; Andriolli A; Donazzan S; Valerio G; Milani M; Crepaldi G
Drugs; 1994; 47 Suppl 2():59-63. PubMed ID: 7517835
[TBL] [Abstract][Full Text] [Related]
67. Time-of-intake (morning versus evening) of extended-release fluvastatin in hyperlipemic patients is without influence on the pharmacodynamics (mevalonic acid excretion) and pharmacokinetics.
Fauler G; Abletshauser C; Erwa W; Löser R; Witschital K; März W
Int J Clin Pharmacol Ther; 2007 Jun; 45(6):328-34. PubMed ID: 17595890
[TBL] [Abstract][Full Text] [Related]
68. Impact of fluvastatin on hyperlipidemia after renal transplantation.
Tokumoto T; Tanabe K; Ishida H; Shimmura H; Ishikawa N; Goya N; Akiba T; Toma H
Transplant Proc; 2004 Sep; 36(7):2141-4. PubMed ID: 15518777
[TBL] [Abstract][Full Text] [Related]
69. Treatment of familial hypercholesterolemia in children and adolescents: effect of lovastatin. Canadian Lovastatin in Children Study Group.
Lambert M; Lupien PJ; Gagné C; Lévy E; Blaichman S; Langlois S; Hayden M; Rose V; Clarke JT; Wolfe BM; Clarson C; Parsons H; Stephure DK; Potvin D; Lambert J
Pediatrics; 1996 May; 97(5):619-28. PubMed ID: 8628597
[TBL] [Abstract][Full Text] [Related]
70. Effects of fluvastatin on hyperlipidemia after renal transplantation: influence of steroid therapy.
Austen JL; Shifrin FA; Bartucci MR; Knauss TC; Schulak JA; Hricik DE
Ann Pharmacother; 1996 Dec; 30(12):1386-9. PubMed ID: 8968448
[TBL] [Abstract][Full Text] [Related]
71. Simvastatin in severe primary hypercholesterolemia: efficacy, safety, and tolerability in 595 patients over 18 weeks. The Principal Investigators.
Simons LA
Clin Cardiol; 1993 Apr; 16(4):317-22. PubMed ID: 8458112
[TBL] [Abstract][Full Text] [Related]
72. Efficacy and safety of an extended-release formulation of fluvastatin for once-daily treatment of primary hypercholesterolemia.
Ballantyne CM; McKenney J; Trippe BS
Am J Cardiol; 2000 Oct; 86(7):759-63. PubMed ID: 11018196
[TBL] [Abstract][Full Text] [Related]
73. The patient at risk: who should we be treating?
Leitersdorf E
Br J Clin Pract Suppl; 1994 Dec; (77):24-7. PubMed ID: 19496269
[TBL] [Abstract][Full Text] [Related]
74. Efficacy and safety of slow-release fluvastatin 80 mg daily in Chinese patients with hypercholesterolemia.
Wu CC; Hsu TL; Chiang HT; Ding PY
J Chin Med Assoc; 2005 Aug; 68(8):353-9. PubMed ID: 16138713
[TBL] [Abstract][Full Text] [Related]
75. Efficacy and safety of fluvastatin in patients with non-insulin-dependent diabetes mellitus and hyperlipidemia.
Knopp RH; Frohlich J; Jokubaitis LA; Dawson K; Broyles FE; Gomez-Coronado D
Am J Med; 1994 Jun; 96(6A):69S-78S. PubMed ID: 8017470
[TBL] [Abstract][Full Text] [Related]
76. A review of current clinical findings with fluvastatin.
Garnett WR
Am J Cardiol; 1996 Sep; 78(6A):20-5. PubMed ID: 8875971
[TBL] [Abstract][Full Text] [Related]
77. [The efficacy, safety and tolerance of fluvastatin sodium 40 mg in patients with hyperlipidemia type IIA].
Fanghänel Salmón G; Salgado Loza JL; Sánchez Reyes L; Padilla Retana JA; Espinosa Campos J
Arch Inst Cardiol Mex; 1996; 66(2):151-6. PubMed ID: 8768633
[TBL] [Abstract][Full Text] [Related]
78. [Fluvastatin].
Teramoto T
Nihon Rinsho; 2001 Mar; 59 Suppl 3():587-91. PubMed ID: 11347136
[No Abstract] [Full Text] [Related]
79. The efficacy and safety of fluvastatin in hypercholesterolemia in renal transplant recipients.
Ghods AJ; Milanian I; Arghani H; Ghadiri G
Transplant Proc; 1995 Oct; 27(5):2579-80. PubMed ID: 7482835
[No Abstract] [Full Text] [Related]
80. Efficacy and safety of treatment with low-dose fluvastatin in hypercholesterolemic renal transplant recipients.
Akiyama T; Ishii T; Imanishi M; Nishioka T; Matsuura T; Kurita T
Transplant Proc; 2001 May; 33(3):2115-8. PubMed ID: 11377469
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
